X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse ALEMBIC PHARMA with ACTAVIS INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs ACTAVIS (US) - Comparison Results

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 ALEMBIC PHARMA   ACTAVIS
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
ACTAVIS
Dec-14
ALEMBIC PHARMA/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs79217,577-   
Low Rs44310,721-   
Sales per share (Unadj.) Rs167.03,165.0-  
Earnings per share (Unadj.) Rs38.2-395.0-  
Cash flow per share (Unadj.) Rs42.0290.4-  
Dividends per share (Unadj.) Rs4.000-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs84.96,864.9-  
Shares outstanding (eoy) m188.52265.90-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.74.5 82.7%   
Avg P/E ratio x16.2-35.8 -45.2%  
P/CF ratio (eoy) x14.748.7 30.2%  
Price / Book Value ratio x7.32.1 352.8%  
Dividend payout %10.50-   
Avg Mkt Cap Rs m116,3833,762,173 3.1%   
No. of employees `000NA21.6 0.0%   
Total wages/salary Rs m4,2140-   
Avg. sales/employee Rs ThNM38,962.3-  
Avg. wages/employee Rs ThNM0-  
Avg. net profit/employee Rs ThNM-4,862.1-  
INCOME DATA
Net Sales Rs m31,487841,585 3.7%  
Other income Rs m55-2,100 -2.6%   
Total revenues Rs m31,542839,484 3.8%   
Gross profit Rs m10,060108,114 9.3%  
Depreciation Rs m722182,234 0.4%   
Interest Rs m3726,545 0.1%   
Profit before tax Rs m9,356-102,766 -9.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m0-7,538 0.0%   
Tax Rs m2,160-5,283 -40.9%   
Profit after tax Rs m7,194-105,021 -6.9%  
Gross profit margin %31.912.8 248.7%  
Effective tax rate %23.15.1 449.1%   
Net profit margin %22.8-12.5 -183.1%  
BALANCE SHEET DATA
Current assets Rs m15,066443,407 3.4%   
Current liabilities Rs m7,674323,374 2.4%   
Net working cap to sales %23.514.3 164.6%  
Current ratio x2.01.4 143.2%  
Inventory Days Days6758 115.4%  
Debtors Days Days4166 61.3%  
Net fixed assets Rs m8,237102,766 8.0%   
Share capital Rs m3770-   
"Free" reserves Rs m15,4160-   
Net worth Rs m16,0051,825,366 0.9%   
Long term debt Rs m0956,528 0.0%   
Total assets Rs m24,5943,345,296 0.7%  
Interest coverage x255.2-2.9 -8,889.1%   
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x1.30.3 508.9%   
Return on assets %29.4-2.3 -1,253.4%  
Return on equity %44.9-5.8 -781.3%  
Return on capital %58.7-3.0 -1,948.8%  
Exports to sales %55.70-   
Imports to sales %10.40-   
Net fx Rs m12,4930-   
CASH FLOW
From Operations Rs m9,304144,516 6.4%  
From Investments Rs m-3,105-346,028 0.9%  
From Financial Activity Rs m-1,959194,418 -1.0%  
Net Cashflow Rs m4,240-7,094 -59.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 64.43 Rs / USD

Compare ALEMBIC PHARMA With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare ALEMBIC PHARMA With: SUN PHARMA  ORCHID PHARMA LTD  IPCA LABS  PLETHICO PHARMA  VENUS REMEDIES  



Today's Market

Sensex Finishes Marginally Lower; Capital Goods & Realty Stocks Fall(Closing)

Indian share markets witnessed selling pressure in the final hour of trade to finish just below the dotted line. At the closing bell, the BSE Sensex closed lower by 71 points.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Feb 20, 2018 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA - PLETHICO PHARMA COMPARISON

COMPARE ALEMBIC PHARMA WITH

MARKET STATS